KROS Stock Overview
A clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Keros Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.44 |
| 52 Week High | US$73.00 |
| 52 Week Low | US$27.02 |
| Beta | 1.25 |
| 11 Month Change | -4.21% |
| 3 Month Change | -29.75% |
| 1 Year Change | 15.06% |
| 33 Year Change | 6.76% |
| 5 Year Change | n/a |
| Change since IPO | 131.27% |
Recent News & Updates
Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
Jun 10Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?
Apr 23
Recent updates
Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
Jun 10Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?
Apr 23We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Sep 24We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Jun 10Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Dec 25Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Sep 08Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07
Aug 04Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Apr 29We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Jan 24Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Oct 10We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
May 05Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?
Mar 13We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate
Jan 19Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?
Nov 27Keros Therapeutics prices equity offering at $50
Nov 13Shareholder Returns
| KROS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.2% | 0.06% | 0.1% |
| 1Y | 15.1% | 9.9% | 24.1% |
Return vs Industry: KROS exceeded the US Biotechs industry which returned 9.9% over the past year.
Return vs Market: KROS underperformed the US Market which returned 24.1% over the past year.
Price Volatility
| KROS volatility | |
|---|---|
| KROS Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: KROS's share price has been volatile over the past 3 months.
Volatility Over Time: KROS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 141 | Jas Seehra | www.kerostx.com |
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases.
Keros Therapeutics, Inc. Fundamentals Summary
| KROS fundamental statistics | |
|---|---|
| Market cap | US$1.68b |
| Earnings (TTM) | -US$160.30m |
| Revenue (TTM) | US$234.00k |
7,161x
P/S Ratio-10.5x
P/E RatioIs KROS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KROS income statement (TTM) | |
|---|---|
| Revenue | US$234.00k |
| Cost of Revenue | US$142.43m |
| Gross Profit | -US$142.19m |
| Other Expenses | US$18.11m |
| Earnings | -US$160.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.44 |
| Gross Margin | -60,765.38% |
| Net Profit Margin | -68,505.13% |
| Debt/Equity Ratio | 0% |
How did KROS perform over the long term?
See historical performance and comparison